The FDA-approved Ventana PATHWAY anti-HER-2/neu (4B5) Rabbit Monoclonal Antibody is intended for the semi-quantitative detection of HER2 antigent in sections of formalin-fixed, paraffin-embedded normal and neoplastic tissue. Created to run on a Ventana automated immunohistochemistry slide staining device, it is indicated as an aid in the assessment of breast cancer patients for whom Herceptin treatement is considered.
PATHWAY anti-HER-2/neu is part of the Ventana rabbit monoclonal breast panel.
Looking for more detailed information?
For regulatory reasons we are not able to provide further details on our products on this website, but more information may be available on our local website.
Please choose your country of residence to access available information in your language.